Azenta

Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Azenta (AZTA) reports robust Q1 earnings, eyes strategic investments

Azenta's Q1 results showcase strong revenue growth and strategic acquisitions, positioning the company for future success. While facing challenges in certain segments, the focus on investments and efficiencies presents opportunities for growth and margin improvement.

Azenta reports mixed Q2 results, focuses on growth initiatives

Azenta's Q2 2023 performance was mixed, with challenges in B Medical impacting revenue but Services business showing resilience and genomics revenue rebounding positively.
Strategic acquisitions, cost actions, and a realignment initiative aim to enhance profitability and drive growth, with a focus on accelerating organic growth and expanding Services business.
Despite margin decreases and revenue challenges, Azenta remains focused on growth initiatives, addressing concerns about distractions and emphasizing opportunities for expansion and profitability.
Management's outlook includes revised revenue guidance, adjusted EBITDA margin expectations, and a commitment to driving profitability through growth initiatives and cost actions.

Azenta reports solid Q3 earnings, eyes growth in China

Azenta's Q3 performance showcased positive financial indicators, with notable growth in key segments and a focus on cost reduction initiatives.
While facing challenges in the Products segment and market share determination, the company remains optimistic about growth opportunities in China and key service offerings.
With a strong focus on sales, marketing, and cost reduction, Azenta aims to sustain its growth trajectory and enhance profitability in the future.

Azenta reports robust Q4 earnings, eyes growth opportunities in 2024

Azenta's Q4 performance was strong, with positive outlook for fiscal 2024 and a commitment to share repurchase.
While facing challenges in gross margins, the company sees opportunities in organic growth and margin expansion.
Strengthening Cell and Gene Therapy business and operational improvements are key focus areas for future growth.
Overall, Azenta remains confident in its ability to outperform the market and enhance profitability.

Azenta reports Q1 revenue decline but sees growth opportunities ahead

Azenta's Q1 performance showed mixed results with revenue decline but growth in key segments. The company remains focused on maintaining guidance and balancing revenue throughout the year.
While facing challenges in B Medical revenue and market dynamics, Azenta has opportunities in sample retrieval programs and financial performance improvements.
Overall, Azenta's strategic focus on key segments and opportunities for growth position the company well for future success, despite current challenges and market conditions.

Azenta reports solid Q2 earnings, eyes growth in China

Azenta's Q2 performance showed revenue growth and improved margins despite challenges.
The company's strengths lie in strong segment growth and market outperformance in China.
Challenges include lower guidance for B Medical and softness in the Instruments segment.
Opportunities arise from pursuing Ascend 2026 plan, NGS shift, and China market growth.

Azenta reports strong Q3 performance and operational profitability growth

Azenta's Q3 results reflect a positive trajectory with revenue growth and improved profitability.
Strategic focus on key segments and the Ascend 2026 program are driving operational efficiency and margin expansion.
While challenges exist in certain segments, opportunities for growth and optimization present a promising outlook for Azenta.

Azenta reports resilient Q4 performance and outlines growth strategies

Azenta's Q4 2024 earnings call highlighted strong financial results, strategic decisions, and future growth initiatives amidst market challenges and uncertainties.
The company's focus on core businesses, competitive strengths in Sample Management Solutions and Multiomics, and commitment to shareholder value enhancement position it for success in 2025.
While facing revenue declines and market-related queries, Azenta's proactive approach to portfolio optimization, operational efficiency, and capital allocation sets the stage for sustainable growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BURLINGTON, Mass. , March 15, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, which includes a presentation beginning at 4:30 pm ET.

Azenta to Participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

BURLINGTON, Mass. , March 7, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.

Azenta Publishes its Environmental, Social, & Governance (ESG) Report

BURLINGTON, Mass. , Feb. 28, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in two upcoming investor conferences: Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7th, 2023.

Azenta to Participate in Upcoming Investor Conferences

An Extension of Azenta's Innovative and Market Leading Automated Cryogenic Technology BURLINGTON, Mass. , Feb. 27, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of the Cryo Store Pico™ ("Pico"), a novel automated cryogenic storage system designed for high-value biological samples used in the many stages of life sciences, from discovery to clinical use.

Azenta Launches Cryo Store Pico™, a Novel Automated Cryogenic Storage System Designed for Clinical and Laboratory Applications

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #DNA--Ansa Biotechnologies, a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company's Board of Directors. Dr. McManus brings decades of experience in the life sciences industry to the Board. He was most recently EVP and Chief Operating Officer at Azenta (NASDAQ:AZTA), a global life sciences tools, products, and services company. Prior to Azenta, Dr.

Ansa Bio Appoints Dr. Matthew McManus as Chair of the Board

Amgen

Globus Medical

1Life Healthcare

Zynex Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off This Month - Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)

Azenta, Inc. (NASDAQ:AZTA ) Q1 2023 Earnings Conference Call February 8, 2023 4:30 PM ET Company Participants Sara Silverman - Head, IR Stephen Schwartz - CEO, President & Director Lindon Robertson - EVP & CFO Conference Call Participants Jacob Johnson - Stephens David Saxon - Needham Paul Knight - KeyBanc Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Operator Greetings, and welcome to the Azenta Q1 2023 Financial Results.

Azenta, Inc. (AZTA) Q1 2023 Earnings Call Transcript

Brooks (AZTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -23.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Brooks (AZTA)

BURLINGTON, Mass. , Feb. 10, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-16, 2023.

Azenta to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Brooks (AZTA) delivered earnings and revenue surprises of 100% and 1.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Azenta (AZTA) Beats Q1 Earnings Estimates

Reported Q1'23 Revenue of $178 Million and Growth of 28% Year-Over-Year Delivered Organic Growth Excluding COVID of 7% Reducing Cost Structure to Deliver Two Points of Margin Enhancement in 2nd Half FY23 BURLINGTON, Mass. , Feb. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2022.

Azenta Reports First Quarter Results For Fiscal 2023, Ended December 31, 2022

BURLINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2023 earnings which ended on December 31, 2022 on Wednesday, February 8, 2023 after the market closes.

Azenta Announces Fiscal 2023 First Quarter Earnings Conference Call and Webcast

Enhances high-throughput workflow offerings with leading 2D barcode reader BURLINGTON, Mass. , Feb. 3, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has acquired Ziath, Ltd.

Azenta Announces the Acquisition of Ziath

BURLINGTON, Mass. , Jan. 5, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 41st Annual J.P.

Azenta to participate in the 41st Annual J.P. Morgan Healthcare Conference

BURLINGTON, Mass. , Jan. 5, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 25th Annual Needham Growth Conference in New York, NY, on Wednesday, January 11, 2023, which includes a presentation beginning at 11:00 am ET.

Azenta to participate in the 25th Annual Needham Growth Conference

Cabot

BOSTON--( BUSINESS WIRE )--Cabot Corporation (NYSE: CBT) is pleased to announce the promotions to Executive Vice President for three senior leaders: Hobart C. Kalkstein, President, Reinforcement Materials Segment, Digital and Americas Region; Erica McLaughlin, Chief Financial Officer (CFO) and Head of Corporate Strategy; and Jeff Zhu, President, Performance Chemicals Segment and Asia Pacific Region. All three continue to report to Sean Keohane, President and Chief Executive Officer.

Cabot Corporation Announces Executive Leadership Promotions

Azenta has done well as a life sciences company. The company has been able to make good strategic acquisitions.

Azenta: Excellence In Life Sciences Offerings

CHELMSFORD, Mass. , Nov. 23, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered into an accelerated share repurchase agreement ("ASR") with JP Morgan Chase Bank, N.A.

Azenta Announces $500 Million Accelerated Share Repurchase Agreement

CHELMSFORD, Mass. , Nov. 21, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the virtual 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, which includes a presentation beginning at 3:30 pm ET.

Azenta to participate in the 5th Annual Evercore ISI HealthCONx Conference

Azenta beat quarterly expectations and announced a $1.5 billion share buyback program, leading AZTA stock to skyrocket Tuesday. The post Azenta Surges To Two-Month High On $1.5 Billion Buyback Despite Covid Decline appeared first on Investor's Business Daily.

Azenta Surges To Two-Month High On $1.5 Billion Buyback Despite Covid Decline

Azenta, Inc. (NASDAQ:AZTA ) Q4 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Sara Silverman - Head, IR Stephen Schwartz - CEO, President & Director Lindon Robertson - EVP & CFO Conference Call Participants Vijay Kumar - Evercore ISI David Saxon - Needham & Company Jacob Johnson - Stephens Inc. Yuan Zhi - B. Riley Securities Operator Greetings, and welcome to the Azenta Q4 2022 Financial Results.

Azenta, Inc. (AZTA) Q4 2022 Earnings Call Transcript

Delivered on Expected Q4'22 Revenue of $138 million Strong Double-Digit Organic Growth Excluding COVID for Q4 and Full Fiscal Year Plan to Repurchase at Least $1 Billion of Common Stock Over the Coming Year, Including $500 Million Accelerated Share Repurchase Program 30% Total Revenue Growth Expected in Fiscal 2023 CHELMSFORD, Mass. , Nov. 14, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2022.

Azenta Reports Fourth Quarter and Full Year Fiscal 2022 Results, Authorizes $1.5 Billion Share Repurchase Program

CHELMSFORD, Mass. , Nov. 9, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Stephens Annual Investment Conference in Nashville, Tennessee, on Wednesday, November 16, 2022, which includes a presentation beginning at 12:00 pm CT.

Azenta to participate in the Stephens Annual Investment Conference

CHELMSFORD, Mass. , Nov. 8, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) and the Government of Luxembourg today announced the signing of a Memorandum of Understanding ("MoU") to facilitate continued healthcare technology development in Luxembourg.

Azenta and the Government of Luxembourg Announce a Memorandum of Understanding to Facilitate Continued Healthcare Technology Development in Luxembourg

Brooks Automation

CHELMSFORD, Mass. , Nov. 7, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2022 earnings which ended on September 30, 2022 on Monday, November 14, 2022 after the market closes.

News for Azenta Stock (AZTA)